MDCX · Medicus Pharma Ltd. Common Stock
View on chartInsiders & Stakes
| VELOCITY FUND PARTNERS, LP 10% Owner | ▼ Sell | Open Market | 3,248,741 Shares held | 5/20/2025 | View profile |
| Bokhari Raza Chief Executive Officer | ▲ Buy | Grant | 2,941,176 Shares held | 9/4/2026 | View profile |
| Bonner Carolyn F. President and CFO | ▲ Buy | Grant | 1,489,493 Shares held | 9/4/2026 | View profile |
| Mehmud Faisal Chief Medical Officer | ▲ Buy | Grant | 1,470,588 Shares held | 9/4/2026 | View profile |
| Smith Andrew Alasdair Chief Operating Officer | ▲ Buy | Grant | 735,458 Shares held | 9/4/2026 | View profile |
| Brennan Edward J. Chief Scientific Officer | ▲ Buy | Grant | 674,735 Shares held | 9/4/2026 | View profile |
| James P. Quinlan Chief Financial Officer | ▲ Buy | Option Exercise | 274,147 Shares held | 8/13/2025 | View profile |
Transaction History
| Smith Andrew Alasdair | ▲ Buy | Grant | 735,294 | $125K | 9/4/2026 |
| Mehmud Faisal | ▲ Buy | Grant | 1,470,588 | $251K | 9/4/2026 |
| Brennan Edward J. | ▲ Buy | Grant | 588,235 | $100K | 9/4/2026 |
| Bonner Carolyn F. | ▲ Buy | Grant | 1,470,588 | $251K | 9/4/2026 |
| Bokhari Raza | ▲ Buy | Grant | 2,941,176 | $501K | 9/4/2026 |
| James P. Quinlan | ▲ Buy | Option Exercise | 125,000 | $101K | 8/13/2025 |
| James P. Quinlan | ▲ Buy | Option Exercise | 20,000 | $55K | 8/13/2025 |
| VELOCITY FUND PARTNERS, LP | ▼ Sell | Open Market | 75,000 | $579K | 5/20/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Medicus Pharma Files Optimized Phase 2b/3 Protocols for Teverelix
Medicus Pharma has filed a streamlined Phase 2b/3 trial design and an optimized registrational protocol for its Teverelix product with the FDA. The filings are aimed at creating a partner‑ready program for advanced prostate cancer treatment. These submissions represent a development milestone that could affect the company’s future regulatory outlook.
Medicus Pharma Files Optimized Phase 2b/3 Protocols for Teverelix. Medicus Pharma has filed a streamlined Phase 2b/3 trial design and an optimized registrational protocol for its Teverelix product with the FDA. The filings are aimed at creating a partner‑ready program for advanced prostate cancer treatment. These submissions represent a development milestone that could affect the company’s future regulatory outlook.